Typ-2-Diabetes mellitus und gastrointestinale Krebsvorsorge

ZUSAMMENFASSUNG

In Deutschland sind mehr als 8 Millionen Menschen diabeteskrank. Patienten mit Typ-2-Diabetes mellitus (T2D) haben ein erhöhtes Risiko für gastrointestinale Adenokarzinome, sie erkranken z. T. früher und weisen i. d. R. ein ungünstigeres, tumorspezifisches 5-Jahres-Überleben auf als Stoffwechselgesunde. Krebs ist nun die Haupttodesursache von Menschen mit T2D. Die chronische Hyperglykämie und die Insulinresistenz können das Wachstum von gastrointestinalen Tumoren begünstigen. So kann T2D Adenokarzinome des Dickdarms, der Bauchspeicheldrüse, der Gallenblase, der Gallengänge, der Leber, des Magens und der Speiseröhre verursachen. Ein gesunder Lebensstil und die Teilnahme an Vorsorgeuntersuchungen sind wichtig und können das tumorbedingte Erkrankungs- und Sterberisiko von T2D-Patienten erheblich verringern.

Publication History

Article published online:
14 October 2022

• Literatur

• 1 Pearson-Stuttard J, Bennett J, Cheng YJ. et al Trends in predominant cau- ses of death in individuals with and without diabetes in England from 2001 to 2018 an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol 2021; 09: 165-173 DOI: 10.1016/S2213-8587(20)30431-9.
• 2 Collier A, Meney C, Hair M. et al Cancer has overtaken cardiovascular dis- ease as the commonest cause of death in Scottish type 2 diabetes pa- tients: A population-based study (The Ayrshire Diabetes Follow-up Cohort study). J Diabetes Investig 2020; 11: 55-61 DOI: 10.1111/jdi.13067.
• 3 Nakamura J, Kamiya H, Haneda M. et al Causes of death in Japanese pa- tients with diabetes based on the results of a survey of 45708 cases du- ring 2001–2010 Report of the Committee on Causes of Death in Diabe- tes Mellitus. J Diabetes Investig 2017; 08: 397-410 DOI: 10.1111/ jdi.12645.
• 4 Dagenais GR, Leong DP, Rangarajan S. et al Variations in common diseases, hospital admissions, and deaths in middle aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2020; 395: 785-794 DOI: 10.1016/S0140-6736(19)32007-0.
• 5 Tsilidis KK, Kasimis JC, Lopez DS. et al Type 2 diabetes and cancer: um- brella review of meta-analyses of observational studies. BMJ 2015; 350: g7607 DOI: 10.1136/bmj.g7607.
• 6 Chen Y, Wu F, Saito E. et al Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium. Diabetologia 2017; 60: 1022-1032 DOI: 10.1007/s00125-017-4229-z.
• 7 Ling S, Brown K, Miksza JK. et al Association of Type 2 Diabetes With Cancer: A Meta-analysis With Bias Analysis for Unmeasured Confounding in 151 Cohorts Comprising 32 Million People. Diabetes Care 2020; 43: 2313-2322 DOI: 10.2337/dc20-0204.
• 8 Saarela K, Tuomilehto J, Sund R. et al Cancer incidence among Finnish people with type 2 diabetes during 1989–2014. Eur J Epidemiol 2019; 34: 259-265 DOI: 10.1007/s10654-018-0438-0.
• 9 Bjornsdottir HH, Rawshani A, Rawshani A.. et al A national observation study of cancer incidence and mortality risks in type 2 diabetes compar- ed to the background population over time. Sci Rep 2020; 10: 17376 DOI: 10.1038/s41598-020-73668-y.
• 10 Sung H, Siegel RL, Rosenberg PS. et al Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health 2019; 04: e137-e147
• 11 Ali Khan U, Fallah M, Sundquist K. et al Risk of colorectal cancer in patients with diabetes mellitus: A Swedish nationwide cohort study. PLoS Med 2020; 17: e1003431
• 12 Lu S, Wang A, Miao S. et al Association between type 2 diabetes and cancer incidence in China: data in hospitalized patients from 2006 to 2013. Ann Transl Med 2020; 08: 176 DOI: 10.21037/atm.2020.01.101.
• 13 Li Z, Chen H, Fritz CD. et al Type 2 Diabetes and Risk of Early-Onset Colorectal Cancer. medRxiv. 2021 DOI: 10.1101/2021.06.02.21257972
• 14 Mikaeel RR, Symonds EL, Kimber J. et al Young-onset colorectal cancer is associated with a personal history of type 2 diabetes. Asia Pac J Clin Oncol 2021; 17: 131-138 DOI: 10.1111/ajco.13428.
• 15 Wang YG, Wang P, Wang B. et al Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One 2014; 09: e95485 DOI: 10.1371/journal.pone.0095485.
• 16 Mao Y, Tao M, Jia X. et al Effect of Diabetes Mellitus on Survival in Pa- tients with Pancreatic Cancer: A Systematic Review and Meta-analysis. Sci Rep 2015; 05: 17102 DOI: 10.1038/srep17102.
• 17 Sheng L, Peng H, Pan Y. et al Evaluating the effect of diabetes on the prognosis of gastric cancer using a propensity score matching method. J Gastrointest Oncol 2020; 11: 999-1008 DOI: 10.21037/jgo-20-375.
• 18 Petrelli F, Ghidini M, Rausa E. et al Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis. Can J Diabetes 2021; 45: 186-197 DOI: 10.1016/j.jcjd.2020.06.009.
• 19 Roderburg C, Loosen SH, Hoyer L. et al Prevalence of diabetes mellitus among 80,193 gastrointestinal cancer patients in five European and three Asian countries. J Cancer Res Clin Oncol 2022; 148: 1057-1062 DOI: 10.1007/ s00432-021-03861-7.
• 20 Ose DJ, Viskochil R, Holowatyj AN. et al Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study. J Natl Compr Canc Netw 2021; 19: 709-718 DOI: 10.6004/jnccn.2020.7653.
• 21 Wagner C, Cadar D, Hackett RA. et al Type 2 diabetes and colorectal cancer screening: Findings from the English Longitudinal Study of Ageing. J Med Screen 2020; 27: 25-30
• 22 Bhatia D, Lega IC, Wu W. et al Breast, cervical and colorectal cancer screening in adults with diabetes: a systematic review and meta-analysis. Diabetologia 2020; 63: 34-48 DOI: 10.1007/s00125-019-04995-7.
• 23 Chuck KW, Hwang M, Choi KS. et al Cancer screening rate in people with diabetes in the Korean population: results from the Korea National He- alth and Nutrition Examination Survey 2007–2009. Epidemiol Health 2017; 39: e2017036 DOI: 10.4178/epih.e2017036.
• 24 Valent F, Gobbato M, Franzo A. et al Diabetes mellitus and colorectal cancer screening in the population of the Italian region Friuli Venezia Giulia. Epidem Biostati Public Health 2017: 14 DOI: 10.2427/11958
• 25 Wu Y, Li Y, Giovannucci E. Potenzial Impact of Time Trend of Lifestyle Risk Factors on Burden of Major Gastrointestinal Cancers in China. Gastroenterology 2021; 161: 1830-1841.e8 DOI: 10.1053/ j.gastro.2021.08.006.
• 26 Li H, Boakye D, Chen X. et al Associations of body mass index at different ages with early-onset colorectal cancer. Gastroenterology 2022; 162: 1088-1097 DOI: 10.1053/j.gastro.2021.12.239.
• 27 GBD 2017 Pancreatic Cancer Collaborators The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2019; 04: 934-947 DOI: 10.1016/S2468-1253(19)30347-4.
• 28 Baecker A, Liu X, La Vecchia C. et al Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev 2018; 27: 205-212 DOI: 10.1097/CEJ.0000000000000428.
• 29 Vuik F, Nieuwenburg S, Bardou M. et al Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 2019; 68: 1820-1826 DOI: 10.1136/gutjnl-2018-317592.
• 30 Scherübl H. Übermäßiges Körpergewicht und Krebsrisiko. Dtsch Med Wochenschr 2020; 145: 1006-1014 DOI: 10.1055/a-1126-3903.
• 31 Rustgi VK, Li Y, Gupta K. et al Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity. Gastroenterology 2021; 161: 171-184.e10 DOI: 10.1053/j.gastro.2021.03.021.
• 32 Sjöholm K, Carlsson LMS, Svensson PA. et al Association of Bariatric Sur- gery With Cancer Incidence in Patients With Obesity and Diabetes: Long-Term Results From the Swedish Obese Subjects Study. Diabetes Care 2021: dc211335 DOI: 10.2337/dc21-1335
• 33 Gallagher EJ, LeRoith D. Hyperinsulinaemia in cancer. Nat Rev Cancer 2020; 20: 629-644 DOI: 10.1038/s41568-020-0295-5.
• 34 https://www.nfcr.org/blog/understanding-the-link-between-sugar-
• 35 Lee SC, Chan JC. Evidence for DNA damage as a biological link between diabetes and cancer. Chin Med J (Engl) 2015; 128: 1543-1548 DOI: 10.4103/0366-6999.157693.
• 36 Chen CL, Yang HI, Yang WS. et al Metabolic factors and risk of hepato- cellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-121 DOI: 10.1053/ j.gastro.2008.03.073.
• 37 Simon TG, King LY, Chong DQ. et al Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology 2018; 67: 1797-1806 DOI: 10.1002/hep.29660.
• 38 Gu J, Yan S, Wang B. et al Type 2 diabetes mellitus and risk of gallblad- der cancer: a systematic review and meta-analysis of observational studies. Diabetes Metab Res Rev 2016; 32: 63-72 DOI: 10.1002/ dmrr.2671.
• 39 Petrick JL, Thistle JE, Zeleniuch-Jacquotte A. et al Body Mass Index, Di abetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Metaanalysis. Am J Gastroenterol 2018; 113: 1494-1505 DOI: 10.1038/s41395-018-0207-4.
• 40 Lai HC, Chang SN, Lin CC. et al Does diabetes mellitus with or without gallstones increase the risk of gallbladder cancer? Results from a population-based cohort study. J Gastroenterol 2013; 48: 856-865 DOI: 10.1007/s00535-012-0683-z.
• 41 Lee BS, Park EC, Park SW. et al Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: a case-control study in Korea. World J Gastroenterol 2015; 21: 502-510 DOI: 10.3748/wjg.v21.i2.502.
• 42 Blackford AL, Canto MI, Klein AP. et al Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. J Natl Cancer Inst 2020; 112: 1162-1169 DOI: 10.1093/jnci/djaa004.
• 43 Yuan C, Babic A, Khalaf N. et al Diabetes, Weight Change, and Pancreatic Cancer Risk. JAMA Oncol 2020; 06: e202948 DOI: 10.1001/jamaon- col.2020.2948.
• 44 Duconseil P, Adham M, Sauvanet A. et al Fukuoka-Negative Branch-Duct IPMNs: When to Worry? A Study from the French Surgical Association (AFC). Ann Surg Oncol 2018; 25: 1017-1025 DOI: 10.1245/s10434-017-6318-0.
• 45 Jun JK, Choi KS, Lee HY. et al Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology 2017; 152: 1319-1328 DOI: 10.1053/j.gastro.2017.01.029.
• 46 Holmberg D, Santoni G, von Euler-Chelpin MC. et al Incidence and Mortality in Upper Gastrointestinal Cancer After Negative Endoscopy for Gastroesophageal Reflux Disease. Gastroenterology 2022; 162: 431-438e4 DOI: 10.1053/ j.gastro.2021.10.003.
• 47 Scherübl H, Cataldegirmen G, Eick J. et al Field cancerization of the up- per aerodigestive tract: Screening for second primary esophageal cancers in cancer survivors. EMJ Oncol 2015; 03: 21-28
• 48 Herrera-Pariente C, Montori S, Llach J. et al Biomarkers for Gastric Cancer Screening and Early Diagnosis. Biomedicines 2021; 09: 1448 DOI: 10.3390/biomedicines9101448.
• 49 Cardoso R, Zhu A, Guo F. et al Inzidenz und Mortalität proximaler und distaler kolorektaler Karzinome in Deutschland – Trends in der Ära der Vorsorgekoloskopie. Dtsch Arztebl Int 2021; 118: 281-287 DOI: 10.3238/arztebl.m2021.0111.
• 50 US Preventive Services Task Force Davidson KW, Barry MJ, Mangione CM. et al Screening for Colorectal Cancer: US Preventive Ser- vices Task Force Recommendation Statement. JAMA 2021; 325: 1965-1977 DOI: 10.1001/jama.2021.6238.